论文部分内容阅读
[目的]评价唑来膦酸治疗既往用过双膦酸盐的实体瘤骨转移患者骨疼痛的缓解效果和安全性。[方法]唑来膦酸4mg静脉注射15min以上,每4周1次,治疗既往用过和未用过双膦酸盐的骨转移实体瘤患者,记录疼痛评分、东方协作肿瘤组织(ECOG)体力状态评分和毒副反应。[结果]疼痛评分较基线下降(P<0.001)。ECOG体力状态评分保持稳定。发热、乏力和恶心是最常见的毒副反应,在既往用过与未用过双膦酸盐患者间毒副反应发生率无统计学意义(P>0.05)。[结论]既往用过双膦酸盐静脉注射治疗的实体瘤骨转移患者,可以安全地给予唑来膦酸治疗。
[Objective] To evaluate the efficacy and safety of zoledronic acid in the treatment of bone pain in patients with solid tumor metastases who had been treated with bisphosphonates. [Methods] 4 mg of zoledronic acid was intravenously injected for more than 15 minutes once every 4 weeks to treat patients with solid tumors of bone metastases who had been treated with or without bisphosphonates, pain scores were recorded, and physical activity of Eastern Cooperative Oncology Tissue (ECOG) Status scores and side effects. [Results] The pain score decreased from baseline (P <0.001). ECOG physical status score remained stable. Fever, fatigue and nausea were the most common side effects. There was no statistically significant (P> 0.05) incidence of side effects between patients with or without bisphosphonates. [Conclusion] Patients with metastatic solid tumors who have been treated with bisphosphonates intravenously can be safely treated with zoledronic acid.